PDK4 INHIBITOR AND USE THEREOF
The purpose of the present invention is to provide a therapeutic agent or preventive agent for exacerbation of influenza, specifically to provide a novel pyruvate dehydrogenase kinase 4 (PDK4) inhibitor. The present invention relates to a PDK4 inhibitor, medical composition or cosmetic composition containing as the active ingredient a compound represented by any one of the following general formulas (I) through (III) and a pharmaceutically acceptable ester derivative thereof, or a pharmaceutically acceptable salt of the same.
1 .- 12 . (canceled)
13 . A PDK4 inhibitor comprising a compound represented by any one of the following formulaes (I) or pharmaceutically acceptable ester derivatives thereof, or pharmaceutically acceptable salts thereof as an active ingredient:
[wherein, R 1 and R 2 can be the same or different and each represent a formyl group or a 2-carboxyphenyliminomethyl group, and R 3 to R 6 can be the same or different and each represents a linear or branched C1-6 alkyl group].
14 . A PDK4 inhibitor comprising a compound represented by any one of the following formulaes (II) or pharmaceutically acceptable ester derivatives thereof, or pharmaceutically acceptable salts thereof as an active ingredient:
[wherein, a bond represented by a solid line and a broken line represents a single bond or a double bond, R 7 and R 8 can be the same or different and each represents a linear or branched C1-6 alkyl group, and R 9 represents a linear or branched C1-6 alkyl group].
15 . A PDK4 inhibitor comprising a compound represented by any one of the following formulaes (III) or pharmaceutically acceptable ester derivatives thereof, or pharmaceutically acceptable salts thereof as an active ingredient:
[wherein, R 10 and R 11 can be the same or different and each represents a linear or branched C1 to 6 alkyl group].
16 . A pharmaceutical composition for diseases or disorders whose development or aggravation is associated with or contributed by the expression or activation of PDK4, comprising a compound represented by any one of the following formulaes (I) or pharmaceutically acceptable ester derivatives thereof, or pharmaceutically acceptable salts thereof as an active ingredient:
[wherein, R 1 and R 2 can be the same or different and each represent a formyl group or a 2-carboxyphenyliminomethyl group, and R 3 to R 6 can be the same or different and each represents a linear or branched C1-6 alkyl group].
17 . A pharmaceutical composition for diseases or disorders whose development or aggravation is associated with or contributed by the expression or activation of PDK4, comprising a compound represented by any one of the following formulaes (II) or pharmaceutically acceptable ester derivatives thereof, or pharmaceutically acceptable salts thereof as an active ingredient:
[wherein, a bond represented by a solid line and a broken line represents a single bond or a double bond, R 7 and R 8 can be the same or different and each represents a linear or branched C1-6 alkyl group, and R 9 represents a linear or branched C1-6 alkyl group].
18 . A pharmaceutical composition for diseases or disorders whose development or aggravation is associated with or contributed by the expression or activation of PDK4, comprising a compound represented by any one of the following formulaes (III) or pharmaceutically acceptable ester derivatives thereof, or pharmaceutically acceptable salts thereof as an active ingredient:
[wherein, R 10 and R 11 can be the same or different and each represents a linear or branched C1 to 6 alkyl group].
19 . The pharmaceutical composition of claim 16 , wherein said diseases or disorders whose development or aggravation is associated with or contributed by the expression or activation of PDK4 is aggravation after influenza infection.
20 . The pharmaceutical composition of claim 16 , wherein said diseases or disorders whose development or aggravation is associated with or contributed by the expression or activation of PDK4 is loss of appetite.
21 . The pharmaceutical composition of claim 16 , wherein said diseases or disorders whose development or aggravation is associated with or contributed by the expression or activation of PDK4 is mitochondrial disease, or a disease or disorder associated with reduced ATP production.
22 . The pharmaceutical composition of claim 16 , wherein said diseases or disorders whose development or aggravation is associated with or contributed by the expression or activation of PDK4 is diabetes.
23 . The pharmaceutical composition of claim 16 , wherein said diseases or disorders whose development or aggravation is associated with or contributed by the expression or activation of PDK4 is cancer.
24 . A cosmetic composition comprising a compound represented by any one of the following formulaes (I) to (III) or pharmaceutically acceptable ester derivatives thereof, or pharmaceutically acceptable salts thereof as an active ingredient:
[wherein, R 1 and R 2 can be the same or different and each represent a formyl group or a 2-carboxyphenyliminomethyl group, and R 3 to R 6 can be the same or different and each represents a linear or branched C1-6 alkyl group];
[wherein, a bond represented by a solid line and a broken line represents a single bond or a double bond, R 7 and R 8 can be the same or different and each represents a linear or branched C1-6 alkyl group, and R 9 represents a linear or branched C1-6 alkyl group];
[wherein, R 10 and R 11 can be the same or different and each represents a linear or branched C1 to 6 alkyl group].
25 . The pharmaceutical composition of claim 17 , wherein said diseases or disorders whose development or aggravation is associated with or contributed by the expression or activation of PDK4 is aggravation after influenza infection.
26 . The pharmaceutical composition of claim 18 , wherein said diseases or disorders whose development or aggravation is associated with or contributed by the expression or activation of PDK4 is aggravation after influenza infection.
27 . The pharmaceutical composition of claim 17 , wherein said diseases or disorders whose development or aggravation is associated with or contributed by the expression or activation of PDK4 is loss of appetite.
28 . The pharmaceutical composition of claim 18 , wherein said diseases or disorders whose development or aggravation is associated with or contributed by the expression or activation of PDK4 is loss of appetite.
29 . The pharmaceutical composition of claim 17 , wherein said diseases or disorders whose development or aggravation is associated with or contributed by the expression or activation of PDK4 is mitochondrial disease, or a disease or disorder associated with reduced ATP production.
30 . The pharmaceutical composition of claim 18 , wherein said diseases or disorders whose development or aggravation is associated with or contributed by the expression or activation of PDK4 is mitochondrial disease, or a disease or disorder associated with reduced ATP production.
31 . The pharmaceutical composition of claim 17 , wherein said diseases or disorders whose development or aggravation is associated with or contributed by the expression or activation of PDK4 is diabetes.
32 . The pharmaceutical composition of claim 18 , wherein said diseases or disorders whose development or aggravation is associated with or contributed by the expression or activation of PDK4 is diabetes.